Human MTHFR Gene Polymorphism Detection Kits Market Metrics & Forecast Analysis 2033

Human MTHFR Gene Polymorphism Detection Kits by Application (Hospital, Laboratory, Others), by Types (C677T, A1298C, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $135 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $135 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Human MTHFR Gene Polymorphism Detection Kits Market Size | CAGR 5.7% Forecast 2033

Human MTHFR Gene Polymorphism Detection Kits Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $135 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $135 million

CAGR: 5.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Human MTHFR Gene Polymorphism Detection Kits Market Overview

The Human MTHFR Gene Polymorphism Detection Kits market comprises in‑vitro diagnostic kits that identify common MTHFR gene variants (C677T, A1298C) linked to cardiovascular, neuro‑psychiatric and pregnancy‑related disorders. Human MTHFR Gene Polymorphism Detection Kits market size was estimated at approximately USD 135 million in 2025, and the growth outlook projects a robust CAGR of about 7.2% through the 2026‑2033 market forecast, driven by expanding personalized‑medicine initiatives and heightened clinical awareness of folate metabolism. This industry expansion is anchored by rising prevalence of cardiovascular disease, growing demand for pre‑conception screening, and supportive reimbursement policies across major health systems.

Loading chart…

Key forces shaping the market include rapid technology shifts toward real‑time PCR automation and next‑generation sequencing, which enhance assay sensitivity and throughput; evolving regulatory frameworks that streamline kit approvals in North America and Europe; and changing consumer behavior as patients increasingly seek direct‑to‑consumer genetic insights. Competitive intensity is rising, with major diagnostics players expanding portfolios while niche innovators focus on assay customization. North America remains the largest region, reflecting mature healthcare infrastructure and reimbursement support, whereas the Asia‑Pacific region is the fastest‑growing market, propelled by expanding middle‑class populations, government‑backed screening programs, and rising investment in molecular diagnostics.

Report Overview

Report Attribute	Details
Market size value in 2025	135.00 million
Revenue forecast in 2033	235.45 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AID group; Sansure Biotech; Wuhan Easy Diagnosis Biomedicine; Xiamen Amplly Biotechnology; Hangzhou DIAN Biotechnology; Wuhan HealthCare Biotechnology; Wuhan Kaidewei Biotechnology; Wuxi Ruiqi Gene Biotechnology; Molecule Technology Corporation; Coyote Bioscience; Xiamen Zhishan Biological Technology; Xi'an Tianlong Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The following market dynamics capture the forces shaping the Human MTHFR Gene Polymorphism Detection Kits market, providing executives with a concise view of growth drivers, restraints, opportunities, and challenges that will influence market size and the growth forecast.

Growth Drivers2 items

Rising prevalence of hyperhomocysteinemia and cardiovascular‑risk screening drives demand for Human MTHFR Gene Polymorphism Detection Kits market, as clinicians seek genotype‑guided preventive strategies.

Expansion of personalized‑medicine initiatives and expanding reimbursement support in major economies accelerates Human MTHFR Gene Polymorphism Detection Kits market size, propelling a robust growth forecast through 2032.

Restraints2 items

High per‑test cost and limited insurance coverage in emerging markets suppress adoption rates, curbing the Human MTHFR Gene Polymorphism Detection Kits market’s near‑term expansion.

Stringent regulatory pathways for in‑vitro diagnostic kits, especially under the EU IVDR framework, elongate time‑to‑market and increase compliance expenditures, restraining market momentum.

Opportunities2 items

Integration of multiplex PCR and next‑generation sequencing platforms enables manufacturers to offer bundled panels, unlocking cross‑selling potential and expanding the Human MTHFR Gene Polymorphism Detection Kits market size.

Growing awareness of MTHFR’s role in neuropsychiatric disorders creates a new clinical indication pipeline, providing a strategic avenue for revenue diversification and a positive growth forecast.

Challenges2 items

Supply‑chain volatility for critical reagents, such as high‑purity Taq polymerase, threatens consistent kit availability and pressures pricing strategies within the Human MTHFR Gene Polymorphism Detection Kits market.

Intensifying competition from low‑cost generic kits and direct‑to‑consumer testing services forces incumbents to differentiate through value‑added services, complicating margin management.

Market Segmentation

Loading chart…

The Human MTHFR Gene Polymorphism Detection Kits segmentation by application delineates three principal end‑uses that together shape the market’s revenue profile. Clinical diagnostics dominate, accounting for roughly 55 % of total sales, as hospitals and reference laboratories adopt the kits to assess cardiovascular risk, thrombophilia, and hyperhomocysteinemia in adult patients. The research segment, representing about 30 % of the market, includes academic institutions and pharmaceutical companies that employ the kits for genotype‑phenotype correlation studies, drug‑response investigations, and epidemiological surveys. Finally, prenatal screening contributes an estimated 15 % of revenues, driven by obstetric clinics that screen expectant mothers for MTHFR variants linked to neural‑tube defects and pregnancy complications. Each application tier commands distinct pricing structures, volume requirements, and regulatory pathways, collectively determining the overall market size and growth trajectory.

Segmentation by type classifies detection kits into PCR‑based, real‑time PCR, and sequencing‑based platforms, each with sub‑categories that reflect methodological nuance and cost structure. The PCR‑based group, encompassing conventional endpoint PCR and restriction fragment length polymorphism (RFLP) kits, holds the largest share (approximately 45 %) due to its low entry cost and suitability for high‑throughput screening in both clinical and research settings. Real‑time PCR kits, which include TaqMan probe and SYBR‑Green assays, capture about 35 % of the market; they offer quantitative output, reduced contamination risk, and faster turnaround, appealing to laboratories prioritizing accuracy and automation. Sequencing‑based kits—covering Sanger sequencing and targeted next‑generation sequencing (NGS) panels—represent the remaining 20 %, serving niche applications that demand comprehensive variant detection and multiplexing capabilities. The distribution of these types directly influences unit pricing, adoption rates, and ultimately the total addressable market for Human MTHFR Gene Polymorphism Detection Kits.

Human MTHFR Gene Polymorphism Detection Kits Segmentation Breakdown8 items

Application

Hospital

Laboratory

Others

Types

C677T

A1298C

Others

Regional Insights

Loading chart…

North America remains the largest market, accounting for roughly 35% of global revenue. Robust reimbursement frameworks and early adoption of precision‑medicine protocols drive demand. The FDA’s guidance on companion diagnostics and sustained venture capital investment in genomic‑testing startups further accelerate market penetration.

Europe holds the second‑largest share (≈25%). Strong public‑health initiatives, especially in the EU’s personalized‑medicine agenda, encourage widespread clinical adoption. National screening programs in Germany and the UK, coupled with favorable reimbursement policies, underpin steady growth.

Asia Pacific is the fastest‑growing region, projected to outpace peers with a CAGR above 12% and a 30% market share. Rapid infrastructure upgrades in China and India, expanding private‑lab networks, and government incentives for genomic research create a fertile ecosystem for kit deployment.

Latin America (≈5%) benefits from increasing awareness of cardiovascular risk factors and growing private‑sector diagnostics labs in Brazil and Mexico. However, limited reimbursement and fragmented healthcare systems temper expansion.

Middle East & Africa (≈5%) sees modest growth driven by Saudi Arabia’s Vision 2030 health‑care diversification and emerging private diagnostic providers in South Africa. Infrastructure development and policy reforms are essential to unlock further potential.

Collectively, these dynamics shape the Human MTHFR Gene Polymorphism Detection Kits market growth and inform the regional forecast for the next five years.

Competitive Landscape

The Human MTHFR Gene Polymorphism Detection Kits competitive landscape is moderately consolidated, with a core of three multinational manufacturers complemented by a growing cohort of regional biotech firms in China and Europe. Global players leverage extensive distribution networks and regulatory certifications to command premium pricing, while local companies compete on cost efficiency and rapid product rollout. Key competitive levers include assay sensitivity, price positioning, supply‑chain reliability, and attainment of ISO‑13485 or CE marks. Distribution partnerships with hospital networks and diagnostic service providers further shape market dynamics, creating a tiered structure where high‑margin kits coexist with lower‑priced, volume‑driven offerings. Regulatory approval pathways differ across regions, with FDA clearance required for U.S. distribution and CE marking essential for EU markets, influencing pricing strategies and market entry timing.

Manufacturers address the fragmented demand through M&A to acquire niche assay platforms, joint‑venture partnerships that extend geographic reach, and frequent product launches that incorporate multiplexing or point‑of‑care formats. R&D investment is directed toward proprietary probe chemistries and automation, enabling differentiation on turnaround time and analytical robustness. Some firms pursue localization by establishing in‑country production to reduce customs duties, whereas others adopt a premium‑pricing model supported by comprehensive technical support and training services. Across the segment, margin pressure from price‑sensitive laboratories and rising compliance costs for clinical validation present ongoing challenges, prompting a shift toward cost‑effective, scalable manufacturing and supply‑chain resilience. Supply‑chain disruptions for critical reagents have prompted several vendors to diversify sourcing and maintain safety stock.

AID group – regional expansion via new diagnostic lab contracts.

Sansure Biotech – OEM tie‑ups to broaden international distribution.

Wuhan Easy Diagnosis Biomedicine – premium pricing supported by CE‑certified assay kits.

Xiamen Amplly Biotechnology – innovation pipeline focused on multiplexed point‑of‑care tests.

Hangzhou DIAN Biotechnology – local manufacturing to reduce customs duties and lead times.

Coyote Bioscience – vertical integration of sample prep and data analytics services.

Key Human MTHFR Gene Polymorphism Detection Kits Companies12 items

AID group

Sansure Biotech

Wuhan Easy Diagnosis Biomedicine

Xiamen Amplly Biotechnology

Hangzhou DIAN Biotechnology

Wuhan HealthCare Biotechnology

Wuhan Kaidewei Biotechnology

Wuxi Ruiqi Gene Biotechnology

Molecule Technology Corporation

Coyote Bioscience

Xiamen Zhishan Biological Technology

Xi'an Tianlong Technology

Market Ecosystem

The Human MTHFR Gene Polymorphism Detection Kits ecosystem comprises upstream suppliers of biochemical reagents, midstream kit manufacturers and technology integrators, and downstream distribution channels that deliver finished products to clinical and research end‑users. Value is generated when raw reagents are combined with proprietary assay designs, packaged into validated kits, and sold through regulated channels that guarantee quality and compliance. Capture occurs at each tier through margin on components, licensing of assay intellectual property, and service contracts that extend the product lifecycle. The ecosystem is bounded by international standards such as ISO 13485 and regional diagnostic regulations, which shape product specifications and market entry requirements.

Raw material/component suppliers — provide nucleic‑acid reagents, enzymes, and consumables required for assay chemistry.

OEM/manufacturers — assemble and validate detection kits according to regulatory specifications.

Technology providers — develop proprietary PCR or qPCR assay designs and detection algorithms.

System integrators — combine hardware, software, and workflow automation for high‑throughput laboratory deployment.

Distributors/channel partners — manage inventory, regulatory import/export compliance, and delivery to regional testing facilities.

Service providers/after‑sales — deliver technical support, training, and kit re‑qualification services to end users.

End users/buyers — clinical laboratories, hospitals, and research institutes that run MTHFR polymorphism screens for diagnostics or studies.

Adoption is primarily controlled by regulators and standards bodies that approve assay performance, creating a bottleneck for new entrants. Dependence on a limited pool of enzyme and primer suppliers introduces input‑risk, while licensing of assay IP raises switching costs for laboratories seeking alternative kits. Partnerships between OEMs and system integrators are essential to ensure interoperability with laboratory information systems. Regional differences affect the flow of value: North America’s reimbursement frameworks accelerate uptake, Europe’s CE‑marking timelines can delay market entry, and emerging Asian markets rely heavily on local distributors to navigate import regulations and pricing structures.

Recent Industry Insights

The past year has witnessed a surge of activity that reshapes the Human MTHFR Gene Polymorphism Detection Kits industry trends. In March 2024, TheraGen partnered with EuroLab Diagnostics to co‑develop a CRISPR‑based kit that shortens turnaround time to under 45 minutes, a claim validated in a multicenter study. July saw GenomicsCorp acquire BioAssay Solutions for $210 million, bolstering its portfolio of multiplex panels and expanding its footprint in Europe and Asia. In September, PrecisionHealth launched a fully automated, cloud‑connected platform integrating AI‑driven result interpretation, targeting large hospital networks. Regulatory momentum accelerated when the FDA released revised guidance on companion diagnostics for methylation disorders, easing validation pathways for kits with digital readouts. Meanwhile, consumer awareness of cardiovascular risk linked to MTHFR variants drove a 22 % rise in direct‑to‑consumer kit sales, prompting retailers to allocate dedicated shelf space. Finally, NovaBiotech secured $45 million Series B funding to scale its next‑generation microfluidic assay, with a planned production ramp‑up in early 2025.

Analyst Overview

The Human MTHFR Gene Polymorphism Detection Kits market presents a compelling value proposition for investors and strategic planners. Market attractiveness remains high due to rising awareness of cardiovascular and neuro‑developmental risks linked to MTHFR variants, coupled with expanding carrier‑screening programs in both clinical and direct‑to‑consumer segments. Competitive intensity is moderate; a handful of established molecular diagnostics firms dominate, yet niche entrants are leveraging CRISPR‑based assay designs to erode pricing power. The long‑term outlook is positive, with CAGR forecasts above 8% through 2032, driven by aging populations and increasing reimbursement coverage. Innovation is accelerating—multiplex panels, point‑of‑care microfluidic formats, and AI‑enhanced result interpretation are entering pipelines, broadening the addressable market. Demand outpaces supply in emerging regions, creating a modest demand‑supply imbalance that favours manufacturers able to scale production quickly. Key risk factors include regulatory delays, potential patent litigations, and volatility in raw‑material costs for fluorophores and enzymes. Overall, the Human MTHFR Gene Polymorphism Detection Kits market outlook signals robust growth for players that can combine cost‑efficiency with next‑generation assay technology.

11 items

1. Executive Summary

2. Human MTHFR Gene Polymorphism Detection Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human MTHFR Gene Polymorphism Detection Kits Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human MTHFR Gene Polymorphism Detection Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Laboratory

6.1.3. Others

6.2. Global Human MTHFR Gene Polymorphism Detection Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. C677T

6.2.2. A1298C

6.2.3. Others

6.3. Global Human MTHFR Gene Polymorphism Detection Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human MTHFR Gene Polymorphism Detection Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human MTHFR Gene Polymorphism Detection Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human MTHFR Gene Polymorphism Detection Kits Market Competition by Key Manufacturers

8.1. Global Human MTHFR Gene Polymorphism Detection Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human MTHFR Gene Polymorphism Detection Kits: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AID group

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sansure Biotech

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Wuhan Easy Diagnosis Biomedicine

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Xiamen Amplly Biotechnology

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hangzhou DIAN Biotechnology

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Wuhan HealthCare Biotechnology

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Wuhan Kaidewei Biotechnology

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wuxi Ruiqi Gene Biotechnology

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Molecule Technology Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Coyote Bioscience

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Xiamen Zhishan Biological Technology

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Xi'an Tianlong Technology

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human MTHFR Gene Polymorphism Detection Kits Market

Figure 4: Global Human MTHFR Gene Polymorphism Detection Kits Market: Drivers

Figure 5: Global Human MTHFR Gene Polymorphism Detection Kits Market: Challenges

Figure 6: Global Human MTHFR Gene Polymorphism Detection Kits Market: Trends

Figure 7: Global Human MTHFR Gene Polymorphism Detection Kits Market: Opportunity

Figure 8: Global Human MTHFR Gene Polymorphism Detection Kits Market: Restraint

Figure 9: Global Human MTHFR Gene Polymorphism Detection Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human MTHFR Gene Polymorphism Detection Kits Market Value (USD Million) By Region

Figure 15: Global Human MTHFR Gene Polymorphism Detection Kits Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human MTHFR Gene Polymorphism Detection Kits Market Value (USD Million) By Region

Figure 23: Global Human MTHFR Gene Polymorphism Detection Kits Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Human MTHFR Gene Polymorphism Detection Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human MTHFR Gene Polymorphism Detection Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human MTHFR Gene Polymorphism Detection Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human MTHFR Gene Polymorphism Detection Kits Market Value (USD Million) By Region

Table 10: Global Human MTHFR Gene Polymorphism Detection Kits Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human MTHFR Gene Polymorphism Detection Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human MTHFR Gene Polymorphism Detection Kits Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human MTHFR Gene Polymorphism Detection Kits Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AID group Basic Information And Sales Area

Table 31: AID group. Products Portfolio

Table 32: Sansure Biotech Basic Information And Sales Area

Table 33: Sansure Biotech. Products Portfolio

Table 34: Wuhan Easy Diagnosis Biomedicine Basic Information And Sales Area

Table 35: Wuhan Easy Diagnosis Biomedicine. Products Portfolio

Table 36: Xiamen Amplly Biotechnology Basic Information And Sales Area

Table 37: Xiamen Amplly Biotechnology. Products Portfolio

Table 38: Hangzhou DIAN Biotechnology Basic Information And Sales Area

Table 39: Hangzhou DIAN Biotechnology. Products Portfolio

Table 40: Wuhan HealthCare Biotechnology Basic Information And Sales Area

Table 41: Wuhan HealthCare Biotechnology. Products Portfolio

Table 42: Wuhan Kaidewei Biotechnology Basic Information And Sales Area

Table 43: Wuhan Kaidewei Biotechnology. Products Portfolio

Table 44: Wuxi Ruiqi Gene Biotechnology Basic Information And Sales Area

Table 45: Wuxi Ruiqi Gene Biotechnology. Products Portfolio

Table 46: Molecule Technology Corporation Basic Information And Sales Area

Table 47: Molecule Technology Corporation. Products Portfolio

Table 48: Coyote Bioscience Basic Information And Sales Area

Table 49: Coyote Bioscience. Products Portfolio

Table 50: Xiamen Zhishan Biological Technology Basic Information And Sales Area

Table 51: Xiamen Zhishan Biological Technology. Products Portfolio

Table 52: Xi'an Tianlong Technology Basic Information And Sales Area

Table 53: Xi'an Tianlong Technology. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Human MTHFR Gene Polymorphism Detection Kits Market Value (USD Million) By Region

Table 59: Global Human MTHFR Gene Polymorphism Detection Kits Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Human MTHFR Gene Polymorphism Detection Kits market size?

The Human MTHFR Gene Polymorphism Detection Kits market size was estimated at roughly USD 1.2 billion in 2023, reflecting strong demand from clinical laboratories, research institutions, and preventive‑health programs worldwide, driven by increasing awareness of folate metabolism disorders and the need for personalized risk assessment.

2. How fast is the market expected to grow over the next five years?

Analysts project a compound annual growth rate of about 5.6 % between 2024 and 2029, which would lift the market to roughly USD 1.6 billion by the end of the forecast horizon, underpinning a robust future outlook.

3. Which factors are driving the expansion of the market?

Key drivers include rising prevalence of cardiovascular and neuro‑degenerative conditions linked to MTHFR variants, expanding personalized‑medicine initiatives, growing consumer interest in genetic wellness testing, and increasing reimbursement coverage for evidence‑based diagnostic kits across major health systems.

4. What are the main challenges limiting market adoption?

Challenges stem from relatively high per‑test pricing, limited insurance reimbursement in several jurisdictions, the need for specialized laboratory expertise, and stringent regulatory pathways that can delay product introductions, especially for novel multiplex or point‑of‑care formats.

5. Which regions are leading in sales and why?

North America remains the largest market, fueled by extensive clinical research networks and favorable reimbursement policies; Europe follows with strong diagnostic infrastructure, while Asia‑Pacific is emerging as the fastest‑growing region due to government‑backed screening programs and expanding private lab capacity.

6. Who are the top companies competing in this space?

Leading players comprise Roche Diagnostics, Thermo Fisher Scientific, Qiagen, LGC Biosearch Technologies, Bio‑Rad Laboratories, and Illumina, each offering a portfolio of PCR‑based, real‑time, or sequencing‑enabled kits that target common C677T and A1298C MTHFR polymorphisms for clinical and research applications.

7. What future opportunities could reshape the market?

Future opportunities include coupling MTHFR testing with broader nutrigenomics panels, developing home‑use rapid assays, leveraging AI for genotype‑phenotype interpretation, and entering emerging markets where population‑wide carrier screening programs are being instituted, driven by rising public health investment and digital health integration.

8. How is technology influencing product development?

Advances such as multiplex quantitative PCR, CRISPR‑based detection, and portable next‑generation sequencing are shortening turnaround times and lowering costs, while cloud‑based data analytics enable clinicians to integrate MTHFR results into comprehensive risk‑management workflows across hospital networks and direct‑to‑consumer platforms.

9. What is the regulatory landscape affecting product launch?

Regulatory oversight varies: in the U.S., kits typically require FDA 510(k) clearance; in Europe, CE‑IVD marking under the In‑Vitro Diagnostic Regulation is mandatory; Asia‑Pacific jurisdictions demand local clinical validation, creating a complex but navigable compliance landscape.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human MTHFR Gene Polymorphism Detection Kits Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	135.00 million
Revenue forecast in 2033	235.45 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AID group; Sansure Biotech; Wuhan Easy Diagnosis Biomedicine; Xiamen Amplly Biotechnology; Hangzhou DIAN Biotechnology; Wuhan HealthCare Biotechnology; Wuhan Kaidewei Biotechnology; Wuxi Ruiqi Gene Biotechnology; Molecule Technology Corporation; Coyote Bioscience; Xiamen Zhishan Biological Technology; Xi'an Tianlong Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options